{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:40:17Z","timestamp":1789155617920,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University Medical Center Utrecht"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study is to assess the effect of efavirenz exposure on neurocognitive functioning and investigate plasma neurofilament light (Nfl) as a biomarker for neurocognitive damage. Sub-analysis of the ESCAPE-study, a randomised controlled trial where virologically suppressed, cognitively asymptomatic HIV patients were randomised (2:1) to switch to rilpivirine or continue on efavirenz. At baseline and week 12, patients underwent an extensive neuropsychological assessment (NPA), and serum efavirenz concentration and plasma Nfl levels were measured. Subgroups of elevated (\u2265\u20094.0\u00a0mg\/L) and therapeutic (0.74 to&lt;\u20094.0\u00a0mg\/L) baseline efavirenz concentration were made. Differences between these groups in baseline NPA Z-scores and in delta scores after efavirenz discontinuation were assessed. Nfl level was measured using an ELISA analysis using single molecule array (Simoa) technology. Correlation of plasma NFL with NPA Z-scores was evaluated using a linear mixed model. The elevated group consisted of 6 patients and the therapeutic group of 48. At baseline, the elevated group showed lower composite Z-scores (median \u2212\u20091.03; IQR 0.87 versus 0.27; 0.79.<jats:italic>p<\/jats:italic>0.02). This effect was also seen on the subdomains verbal (<jats:italic>p<\/jats:italic>0.01), executive functioning (<jats:italic>p<\/jats:italic>0.02), attention (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.01) and speed (<jats:italic>p<\/jats:italic>0.01). In the switch group, the elevated group improved more on composite scores after discontinuing efavirenz (mean 0.58; SD 0.32 versus 0.22; 0.54,<jats:italic>p<\/jats:italic>0.15). No association between plasma Nfl and composite Z-score was found. High efavirenz exposure is associated with worse cognitive functioning compared with patients with therapeutic concentrations. Plasma Nfl is not a suitable biomarker to measure cognitive damage in this group.<\/jats:p>","DOI":"10.1007\/s13365-020-00860-1","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T23:04:01Z","timestamp":1591830241000},"page":"572-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0164-7282","authenticated-orcid":false,"given":"Charlotte S.","family":"Hakkers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik M.","family":"van Maarseveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop E.","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy I. M.","family":"Hoepelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"860_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40263-013-0132-4","volume":"28","author":"MS Abers","year":"2014","unstructured":"Abers MS, Shandera WX, Kass JS (2014) Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 28:131\u2013145. https:\/\/doi.org\/10.1007\/s40263-013-0132-4","journal-title":"CNS Drugs"},{"key":"860_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13365-018-0664-y","volume":"24","author":"AM Anderson","year":"2018","unstructured":"Anderson AM, Easley KA, Kasher N, Franklin D, Heaton RK, Zetterberg H, Blennow K, Gisslen M, Letendre SL (2018) Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. J Neuro-Oncol 24:695\u2013701. https:\/\/doi.org\/10.1007\/s13365-018-0664-y","journal-title":"J Neuro-Oncol"},{"key":"860_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1517\/14740338.6.2.147","volume":"6","author":"G Arendt","year":"2007","unstructured":"Arendt G, de Nocker D, von Giesen H-J, Nolting T (2007) Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 6:147\u2013154. https:\/\/doi.org\/10.1517\/14740338.6.2.147","journal-title":"Expert Opin Drug Saf"},{"key":"860_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.neuron.2016.07.007","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:494\u2013496. https:\/\/doi.org\/10.1016\/j.neuron.2016.07.007","journal-title":"Neuron"},{"key":"860_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1124\/mol.115.098590","volume":"88","author":"L Bertrand","year":"2015","unstructured":"Bertrand L, Toborek M (2015) Dysregulation of endoplasmic reticulum stress and autophagic responses by the antiretroviral drug efavirenz. Mol Pharmacol 88:304\u2013315. https:\/\/doi.org\/10.1124\/mol.115.098590","journal-title":"Mol Pharmacol"},{"key":"860_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090350","volume":"9","author":"L Borand","year":"2014","unstructured":"Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Prak N, Kim C, Lak KK, Hak C, Dim B, Nerrienet E, Fontanet A, Sok T, Goldfeld AE, Blanc FX, Taburet AM (2014) Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). PLoS One 9:e90350. https:\/\/doi.org\/10.1371\/journal.pone.0090350","journal-title":"PLoS One"},{"key":"860_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","volume":"61","author":"D Burger","year":"2006","unstructured":"Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, Schenk P, van Schaik R (2006) Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 61:148\u2013154. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02536.x","journal-title":"Br J Clin Pharmacol"},{"key":"860_CR8","unstructured":"Burgess PW, Shallice T (1997) The hayling and Brixton tests"},{"key":"860_CR9","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1007\/s11064-017-2358-x","volume":"42","author":"VT Ciavatta","year":"2017","unstructured":"Ciavatta VT, Bichler EK, Speigel IA, Elder CC, Teng SL, Tyor WR, Garc\u00eda PS (2017) In vitro and ex vivo neurotoxic effects of efavirenz are greater than those of other common antiretrovirals. Neurochem Res 42:3220\u20133232. https:\/\/doi.org\/10.1007\/s11064-017-2358-x","journal-title":"Neurochem Res"},{"key":"860_CR10","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1212\/WNL.0b013e31821670fb","volume":"76","author":"N Ciccarelli","year":"2011","unstructured":"Ciccarelli N, Fabbiani M, Di Giambenedetto S et al (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76:1403\u20131409. https:\/\/doi.org\/10.1212\/WNL.0b013e31821670fb","journal-title":"Neurology"},{"key":"860_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1517\/14740338.2013.823396","volume":"12","author":"EH Decloedt","year":"2013","unstructured":"Decloedt EH, Maartens G (2013) Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf 12:841\u2013846. https:\/\/doi.org\/10.1517\/14740338.2013.823396","journal-title":"Expert Opin Drug Saf"},{"key":"860_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1365-2044.2005.04208.x","volume":"60","author":"V Fodale","year":"2005","unstructured":"Fodale V, Mazzeo A, Pratic\u00f2 C, Aguennouz M, Toscano A, Santamaria LB, Vita G (2005) Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. Anaesthesia 60:806\u2013810. https:\/\/doi.org\/10.1111\/j.1365-2044.2005.04208.x","journal-title":"Anaesthesia"},{"key":"860_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1586\/14787210.2016.1157469","volume":"14","author":"R Gaida","year":"2016","unstructured":"Gaida R, Truter I, Grobler C, Kotze T, Godman B (2016) A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Expert Rev Anti-Infect Ther 14:377\u2013388. https:\/\/doi.org\/10.1586\/14787210.2016.1157469","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"860_CR14","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1086\/380791","volume":"38","author":"L Gallego","year":"2004","unstructured":"Gallego L, Barreiro P, del R\u00edo R et al (2004) Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis 38:430\u2013432. https:\/\/doi.org\/10.1086\/380791","journal-title":"Clin Infect Dis"},{"key":"860_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gissl\u00e9n","year":"2016","unstructured":"Gissl\u00e9n M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H (2016) Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3:135\u2013140. https:\/\/doi.org\/10.1016\/j.ebiom.2015.11.036","journal-title":"EBioMedicine"},{"key":"860_CR16","unstructured":"Gronwall D, Samspon H (1974) The psychological effects of concussion"},{"key":"860_CR17","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1086\/497835","volume":"41","author":"F Gutierrez","year":"2005","unstructured":"Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, Borras J, Martin-Hidalgo A (2005) Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41:1648\u20131653. https:\/\/doi.org\/10.1086\/497835","journal-title":"Clin Infect Dis"},{"key":"860_CR18","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1097\/QAI.0000000000001876","volume":"80","author":"CS Hakkers","year":"2019","unstructured":"Hakkers CS, Arends JE, van den Berk GE, Ensing MHM, Hooijenga I, Vink M, van Zandvoort MJE, Hoepelman AIM (2019) Objective and subjective improvement of cognition after discontinuing efavirenz in asymptomatic patients. JAIDS J Acquir Immune Defic Syndr 80:e14\u2013e22. https:\/\/doi.org\/10.1097\/QAI.0000000000001876","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"860_CR19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","volume":"10","author":"BS Kappelhoff","year":"2005","unstructured":"Kappelhoff BS, van Leth F, Robinson PA, MacGregor T, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD, 2NN Study Group (2005) Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 10:489\u2013498","journal-title":"Antivir Ther"},{"key":"860_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1352458512458010","volume":"19","author":"M Khalil","year":"2013","unstructured":"Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A, Vane MLG, Wallner-Blazek M, Bachmaier G, Archelos JJ, Koel-Simmelink MJA, Blankenstein MA, Fuchs S, Fazekas F, Teunissen CE (2013) CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 19:436\u2013442. https:\/\/doi.org\/10.1177\/1352458512458010","journal-title":"Mult Scler"},{"key":"860_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/ene.13389","volume":"24","author":"GG Kovacs","year":"2017","unstructured":"Kovacs GG, Andreasson U, Liman V, Regelsberger G, Lutz MI, Danics K, Keller E, Zetterberg H, Blennow K (2017) Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol 24:1326\u20131e77. https:\/\/doi.org\/10.1111\/ene.13389","journal-title":"Eur J Neurol"},{"key":"860_CR22","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius \u00c5, Liman V, Norgren N, Blennow K, Zetterberg H (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54:1655\u20131661. https:\/\/doi.org\/10.1515\/cclm-2015-1195","journal-title":"Clin Chem Lab Med"},{"key":"860_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","volume":"88","author":"J Kuhle","year":"2017","unstructured":"Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, Yaldizli \u00d6, Pelletier D, Giovannoni G, Waubant E, Gnanapavan S (2017) Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88:826\u2013831. https:\/\/doi.org\/10.1212\/WNL.0000000000003653","journal-title":"Neurology"},{"key":"860_CR24","first-page":"93","volume-title":"Neurofilament light chain determination from peripheral blood samples","author":"M Limberg","year":"2015","unstructured":"Limberg M, Disanto G, Barro C, Kuhle J (2015) Neurofilament light chain determination from peripheral blood samples. Humana Press, New York, NY, pp 93\u201398"},{"key":"860_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C Marzolini","year":"2001","unstructured":"Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71\u201375","journal-title":"AIDS"},{"key":"860_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D, Laforce RJ, Masellis M, Vandenberghe R, Ber IL, Otto M, van Minkelen R, Papma JM, Rombouts SA, Balasa M, \u00d6ijerstedt L, Jelic V, Dick KM, Cash DM, Harding SR, Jorge Cardoso M, Ourselin S, Rossor MN, Padovani A, Scarpini E, Fenoglio C, Tartaglia MC, Lamari F, Barro C, Kuhle J, Rohrer JD, Teunissen CE, van Swieten JC (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3:623\u2013636. https:\/\/doi.org\/10.1002\/acn3.325","journal-title":"Ann Clin Transl Neurol"},{"key":"860_CR27","first-page":"103","volume":"11","author":"JA Mu\u00f1oz-Moreno","year":"2009","unstructured":"Mu\u00f1oz-Moreno JA, Fumaz CR, Ferrer MJ et al (2009) Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev 11:103\u2013109","journal-title":"AIDS Rev"},{"key":"860_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00228-013-1634-1","volume":"70","author":"P Naidoo","year":"2014","unstructured":"Naidoo P, Chetty VV, Chetty M (2014) Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur J Clin Pharmacol 70:379\u2013389. https:\/\/doi.org\/10.1007\/s00228-013-1634-1","journal-title":"Eur J Clin Pharmacol"},{"key":"860_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00126334-200112010-00015","volume":"28","author":"M N\u00fa\u00f1ez","year":"2001","unstructured":"N\u00fa\u00f1ez M, Gonz\u00e1lez de Requena D, Gallego L et al (2001) Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 28:399\u2013400","journal-title":"J Acquir Immune Defic Syndr"},{"key":"860_CR30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/ana.20816","volume":"59","author":"JA Pettersen","year":"2006","unstructured":"Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, Gill MJ, Power C (2006) Sensory neuropathy in human immunodeficiency virus\/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 59:816\u2013824. https:\/\/doi.org\/10.1002\/ana.20816","journal-title":"Ann Neurol"},{"key":"860_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1177\/1352458517715132","volume":"135245851771513","author":"F Piehl","year":"2017","unstructured":"Piehl F, Kockum I, Khademi M, Blennow K, Lycke J, Zetterberg H, Olsson T (2017) Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler J 135245851771513:1046\u20131054. https:\/\/doi.org\/10.1177\/1352458517715132","journal-title":"Mult Scler J"},{"key":"860_CR32","unstructured":"Reitan RM, Wolfson D (1985) The Halstead-Reitan Neuropsychological Test Battery: therapy and clinical interpretation"},{"key":"860_CR33","first-page":"286","volume":"28","author":"A Rey","year":"1941","unstructured":"Rey A (1941) The Rey Auditory Verbal Learning Test. L\u2019examen psychologique dans les cas d\u2019enc\u00e9phalopathie traumatique. Arch Psychol (Geneve) 28:286\u2013340","journal-title":"Arch Psychol (Geneve)"},{"key":"860_CR34","unstructured":"Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I (1994) The test of everyday attention"},{"key":"860_CR35","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1212\/WNL.0b013e3181d9ed09","volume":"74","author":"KR Robertson","year":"2010","unstructured":"Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ, For the A5170 Study Team (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74:1260\u20131266","journal-title":"Neurology"},{"key":"860_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s13365-012-0120-3","volume":"18","author":"K Robertson","year":"2012","unstructured":"Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. JNeurovirol 18:388\u2013399. https:\/\/doi.org\/10.1007\/s13365-012-0120-3","journal-title":"JNeurovirol"},{"key":"860_CR37","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IOC, Dick KM, Brotherhood E, Gordon E, Fellows A, Toombs J, Druyeh R, Cardoso MJ, Ourselin S, Nicholas JM, Norgren N, Mead S, Andreasson U, Blennow K, Schott JM, Fox NC, Warren JD, Zetterberg H (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87:1329\u20131336. https:\/\/doi.org\/10.1212\/WNL.0000000000003154","journal-title":"Neurology"},{"key":"860_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/acn3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, Kramer JH, Rosen H, Miller BL, Zetterberg H, Boxer AL (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:216\u2013225. https:\/\/doi.org\/10.1002\/acn3.290","journal-title":"Ann Clin Transl Neurol"},{"key":"860_CR39","doi-asserted-by":"crossref","unstructured":"Roy EA, Square-Storer PA (1994) Neuropsychology of movement sequencing disorders and apraxia","DOI":"10.1016\/B978-0-08-092668-1.50015-6"},{"key":"860_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/BF03078128","volume":"39","author":"B Schmand","year":"2008","unstructured":"Schmand B, Groenink SC, van den Dungen M (2008) Letterfluency: psychometrische eigenschappen en Nederlandse normen. Tijdschr Gerontol Geriatr 39:64\u201376","journal-title":"Tijdschr Gerontol Geriatr"},{"key":"860_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0892-0362(96)00088-8","volume":"18","author":"LC Schmued","year":"1996","unstructured":"Schmued LC, Albertson CM, Andrews A, Sandberg JA, Nickols J, Slikker W Jr (1996) Evaluation of brain and nerve pathology in rats chronically dosed with ddI or isoniazid. Neurotoxicol Teratol 18:555\u2013563. https:\/\/doi.org\/10.1016\/0892-0362(96)00088-8","journal-title":"Neurotoxicol Teratol"},{"key":"860_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12640-016-9646-0","volume":"30","author":"A Shah","year":"2016","unstructured":"Shah A, Gangwani MR, Chaudhari NS, Glazyrin A, Bhat HK, Kumar A (2016) Neurotoxicity in the post-HAART era: caution for the antiretroviral therapeutics. Neurotox Res 30:677\u2013697. https:\/\/doi.org\/10.1007\/s12640-016-9646-0","journal-title":"Neurotox Res"},{"key":"860_CR43","doi-asserted-by":"publisher","first-page":"38737","DOI":"10.1038\/srep38737","volume":"6","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Blennow K, Halbgebauer S, Shi S, Ruf V, Oeckl P, Giese A, Kuhle J, Slivarichova D, Zetterberg H, Otto M (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep 6:38737. https:\/\/doi.org\/10.1038\/srep38737","journal-title":"Sci Rep"},{"key":"860_CR44","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11011-008-9109-2","volume":"23","author":"EL Streck","year":"2008","unstructured":"Streck EL, Scaini G, Rezin GT, Moreira J, Fochesato CM, Rom\u00e3o PRT (2008) Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metab Brain Dis 23:485\u2013492. https:\/\/doi.org\/10.1007\/s11011-008-9109-2","journal-title":"Metab Brain Dis"},{"key":"860_CR45","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1124\/jpet.112.195701","volume":"343","author":"LB Tovar-y-Romo","year":"2012","unstructured":"Tovar-y-Romo LB, Bumpus NN, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ (2012) Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 343:696\u2013703. https:\/\/doi.org\/10.1124\/jpet.112.195701","journal-title":"J Pharmacol Exp Ther"},{"key":"860_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1017\/S1355617706060115","volume":"12","author":"W Van der Elst","year":"2006","unstructured":"Van der Elst W, Van Boxtel MPJ, Van Breukelen GJP, Jolles J (2006) Normative data for the animal, profession and letter M naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 12:80\u201389. https:\/\/doi.org\/10.1017\/S1355617706060115","journal-title":"J Int Neuropsychol Soc"},{"key":"860_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000422","volume":"5","author":"KN Varhaug","year":"2018","unstructured":"Varhaug KN, Barro C, Bj\u00f8rnevik K, Myhr KM, Torkildsen \u00d8, Wergeland S, Bindoff LA, Kuhle J, Vedeler C (2018) Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflammation 5:e422. https:\/\/doi.org\/10.1212\/NXI.0000000000000422","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"860_CR48","unstructured":"Verhage F (1964) Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar. University of Groningen"},{"key":"860_CR49","unstructured":"Wechsler D (2013) Wechsler adult intelligence scale - fourth edition - Nederlandstalige bewerking"},{"key":"860_CR50","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/jnnp-2015-312972","volume":"87","author":"C Wilke","year":"2016","unstructured":"Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C, Maia L, Maetzler W, Kuhle J, Synofzik M (2016) Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry 87:1270\u20131272. https:\/\/doi.org\/10.1136\/jnnp-2015-312972","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"860_CR51","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/JCLINPATH-2013-202069","volume":"67","author":"H Xu","year":"2014","unstructured":"Xu H, Wang Z, Zheng L, Zhang W, Lv H, Jin S, Yuan Y (2014) Lamivudine\/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. J Clin Pathol 67:999\u20131005. https:\/\/doi.org\/10.1136\/JCLINPATH-2013-202069","journal-title":"J Clin Pathol"},{"key":"860_CR52","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","volume":"17","author":"A Yilmaz","year":"2017","unstructured":"Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, Spudich S, Underwood J, Zetterberg H, Gissl\u00e9n M (2017) Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn 17:761\u2013770. https:\/\/doi.org\/10.1080\/14737159.2017.1341313","journal-title":"Expert Rev Mol Diagn"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-020-00860-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-020-00860-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-020-00860-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T20:07:52Z","timestamp":1666901272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-020-00860-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1007\/s13365-020-00860-1","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed according to the declaration of Helsinki and was reviewed and approved by the medical ethical board of the University Medical Center Utrecht. All participants signed written informed consent","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}